Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Crossref DOI link: https://doi.org/10.1186/s40425-017-0276-8
Published Online: 2017-09-19
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kaufman, Howard L.
Andtbacka, Robert H. I.
Collichio, Frances A.
Wolf, Michael
Zhao, Zhongyun
Shilkrut, Mark
Puzanov, Igor
Ross, Merrick
Funding for this research was provided by:
Amgen Inc.